Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
64Cu-porphysomes (University Health Network)
- Development stage
- Unknown
- Lead developer
- University Health Network
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
64Cu-porphysomes are inherently multimodal, all-organic nanoparticles composed of self-assembled porphyrin-lipid conjugates. Developed by the University Health Network (UHN), these nanovesicles (porphysomes) utilize the intrinsic metal-chelating properties of the porphyrin bilayer to stably incorporate Copper-64 (64Cu), enabling high-sensitivity positron emission tomography (PET) imaging. Beyond radiotracing, the nanoparticles exhibit unique biophotonic properties, including structure-dependent fluorescence self-quenching and photoacoustic signaling, which allow for multimodal tumor delineation. They primarily accumulate in cancerous tissues through the enhanced permeability and retention (EPR) effect. Clinical development is focused on the imaging and staging of advanced metastatic gynecological cancers, while preclinical studies have demonstrated efficacy in prostate cancer models.
- Other names
- 64Cu-PORPHYSOMESCopper-64 labelled porphysomesCopper64 labelled porphysomesCopper 64 labelled porphysomes64Cu-labeled porphyrin-lipid nanoparticles
Beyond the preview
Go deeper on 64Cu-porphysomes (University Health Network).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 64Cu-porphysomes (University Health Network).